RE:ONCY enters a new phase in company's evolution"Our continued progress in breast cancer and the highly-promising pancreatic cancer data we reported earlier today have pelareorep moving confidently towards pivotal trials in both of these indications for which new treatment options are needed"
... some on this message board just can't seem to grasp this development and how ONCY has evolved into multi-indication cancer company.